Stereoselective handling of perhexiline: implications regarding accumulation within the human myocardium

Simple item page
dc.contributor.authorChong, C.
dc.contributor.authorDrury, N.
dc.contributor.authorLicari, G.
dc.contributor.authorFrenneaux, M.
dc.contributor.authorHorowitz, J.
dc.contributor.authorPagano, D.
dc.contributor.authorSallustio, B.
dc.date.issued2015
dc.description.abstractPurpose: Perhexiline is a prophylactic anti-ischaemic agent with weak calcium antagonist effect which has been increasingly utilised in the management of refractory angina. The metabolic clearance of perhexiline is modulated by CYP2D6 metaboliser status and stereoselectivity. The current study sought to (1) determine whether the acute accumulation of perhexiline in the myocardium is stereoselective and (2) investigate the relationship between duration of short-term therapy and the potential stereoselective effects of perhexiline within myocardium. Method: Patients (n  = 129) from the active arm of a randomised controlled trial of preoperative perhexiline in cardiac surgery were treated with oral perhexiline for a median of 9 days. Correlates of atrial and ventricular concentrations of enantiomers were sought via univariate followed by multivariate analyses. Results: Myocardial uptake of both (+) and (−) perhexiline was greater in ventricles than in atria, and there was more rapid clearance of (−) than (+) perhexiline. The main determinants of atrial uptake of both (+) and (−) perhexiline were the plasma concentrations [(+) perhexiline: β = −0.256, p = 0.015; (−) perhexiline: β = −0.347, p = 0.001] and patients’ age [(+) perhexiline: β = 0.300, p = 0.004; (−) perhexiline: β = 0.288, p = 0.005]. Atrial uptake of (+) enantiomer also varied directly with duration of therapy (β = 0.228, p = 0.025), while atrial uptake of (−) perhexiline varied inversely with simultaneous heart rate (β = −0.240, p = 0.015).
dc.description.statementofresponsibilityCher-Rin Chong, Nigel E. Drury, Giovanni Licari, Michael P. Frenneaux, John D. Horowitz, Domenico Pagano, Benedetta C. Sallustio
dc.identifier.citationEuropean Journal of Clinical Pharmacology, 2015; 71(12):1485-1491
dc.identifier.doi10.1007/s00228-015-1934-8
dc.identifier.issn0031-6970
dc.identifier.issn1432-1041
dc.identifier.orcidChong, C. [0000-0001-8722-8937]
dc.identifier.orcidLicari, G. [0000-0002-4056-0681]
dc.identifier.orcidHorowitz, J. [0000-0001-6883-0703]
dc.identifier.orcidSallustio, B. [0000-0002-0186-3073]
dc.identifier.urihttp://hdl.handle.net/2440/99956
dc.language.isoen
dc.publisherSpringer
dc.relation.grantNHMRC
dc.rights© Springer-Verlag Berlin Heidelberg 2015
dc.source.urihttps://doi.org/10.1007/s00228-015-1934-8
dc.subjectPerhexiline
dc.subjectmetabolism
dc.subjectpharmacokinetics
dc.subjectdrug uptake
dc.subjectstereoselectivity
dc.titleStereoselective handling of perhexiline: implications regarding accumulation within the human myocardium
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications